![A photo of Ian Dunham, the Director of Open Targets, and the following quote: "The rich phenotypic information and special characteristics of the FinnGen data make it a very high priority resource for Open Targets".](https://www2.helsinki.fi/sites/default/files/styles/12_7_small/public/thumbnails/image/ian_dunham-uhsize.png?itok=whOU7FbD "A photo of Ian Dunham, the Director of Open Targets, and the following quote: "The rich phenotypic information and special characteristics of the FinnGen data make it a very high priority resource for Open Targets".")
Large genomic analysis highlights COVID-19 risk factors
An international collaboration uncovers several genetic markers associated with SARS-CoV-2 infection and COVID-19 severity.
FIMM
Institute for Molecular Medicine Finland, HiLIFE
Building a bridge from discovery to medicine
OUR MISSION: FIMM is a translational institute with a driving mission to perform innovative research on patients and populations - utilizing molecular, genomic and health data – targeted towards understanding drivers of health and disease and delivering improvements to the safety, efficacy and efficiency of healthcare in Finland and beyond.
FIMM News
COVID-19 Research
Insights into how to better understand and treat COVID-19 are desperately needed. This page summarizes the FIMM efforts in contributing our researchers' expertise, technology and time to help to beat the COVID-19 pandemic.
FIMM on Twitter
Follow FIMM on Twitter for real-time news updates!
Helsinki Institute of Life Science
In close collaboration with:
